Dihexa vs Cartalax
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Dihexa is a potent experimental oligopeptide derived from angiotensin IV that dramatically enhances synaptogenesis. Preclinical research shows cognitive enhancement orders of magnitude more potent than BDNF — it is considered one of the most powerful nootropic compounds in research, but has very limited human safety data.
- Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
- Half-Life
- Unknown (limited pharmacokinetic data)
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- Oral, SubQ, Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 5–10 mg
- 10 mg per day
- Frequency
- Daily
- Daily for 10–30 days
- Key Benefits
- Dramatically increases synapse formation (potentially 10 million× more potent than BDNF in animal models)
- Enhances memory and learning
- May reverse cognitive decline
- Improves neuroplasticity and executive function
- Long-lasting cognitive benefits from short courses
- Potential therapeutic agent for Alzheimer's
- Supports cartilage matrix synthesis and maintenance
- May slow progression of osteoarthritic cartilage degradation
- Reduces chondrocyte apoptosis
- Promotes joint longevity in aging and high-impact sports
- Anti-aging effects on connective tissue
- Complementary to BPC-157 and TB-500 in joint recovery protocols
- Well tolerated in available human and animal research
- Side Effects
- Headache
- Irritability
- Brain fog during washout period
- Unknown long-term effects (insufficient data)
- Generally well tolerated
- Mild injection site reactions
- No significant adverse events reported at standard doses
- Stacks With
- —
- —